NUTX Stock Analysis: Nutex Health | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.352m USD | 12M Return: 56.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.7M
Qual. Beats: 0
Rev. Trend: 96.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nutex Health Inc. (NUTX) is a Houston-based healthcare services provider operating through three integrated segments: Hospital, Population Health Management (PHM), and Real Estate. The company specializes in the development and management of micro-hospitals, which are small-scale inpatient facilities typically housing between eight and fifteen beds to provide emergency and acute care in underserved or high-demand suburban areas.
The Hospital segment offers emergency services, diagnostic imaging, and laboratory testing, while the PHM division utilizes a proprietary cloud-based platform to manage Independent Physician Associations (IPAs). This integrated business model allows the company to capture value across the healthcare delivery chain, from clinical services to the ownership of the underlying medical real estate. Micro-hospitals often benefit from lower overhead costs compared to traditional large-scale medical centers while maintaining similar reimbursement structures for emergency care.
Investors should evaluate the companys expansion strategy and regional market density using the analytical tools available on ValueRay. Nutex Health transitioned to the public markets in April 2022 and continues to focus on scaling its network of specialty hospitals and outpatient departments across the United States.
- Micro-hospital expansion and facility utilization rates drive Hospital segment revenue
- PHM segment growth depends on IPA network scaling and physician recruitment
- Managed care contract negotiations impact reimbursement rates and operating margins
- High debt levels and capital requirements for new facility development influence liquidity
| Net Income: 96.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 18.99 > 1.0 |
| NWC/Revenue: 44.91% < 20% (prev 36.03%; Δ 8.88% < -1%) |
| CFO/TA 0.28 > 3% & CFO 272.7m > Net Income 96.4m |
| Net Debt (449.7m) to EBITDA (297.2m): 1.51 < 3 |
| Current Ratio: 3.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.18m) vs 12m ago 22.63% < -2% |
| Gross Margin: 47.47% > 18% (prev 48.77%; Δ -1.30% > 0.5%) |
| Asset Turnover: 102.4% > 50% (prev 81.94%; Δ 20.43% > 0%) |
| Interest Coverage Ratio: 13.29 > 6 (EBIT TTM 276.2m / Interest Expense TTM 20.8m) |
| A: 0.41 (Total Current Assets 579.6m - Total Current Liabilities 184.4m) / Total Assets 957.3m |
| B: -0.25 (Retained Earnings -239.4m / Total Assets 957.3m) |
| C: 0.32 (EBIT TTM 276.2m / Avg Total Assets 859.6m) |
| D: 0.67 (Book Value of Equity 346.3m / Total Liabilities 515.3m) |
| Altman-Z'' = 4.76 = AA |
| DSRI: 0.80 (Receivables 339.6m/299.3m, Revenue 880.0m/624.3m) |
| GMI: 1.03 (GM 48.77% / 47.47%) |
| AQI: 0.70 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.41 (Revenue 880.0m / 624.3m) |
| TATA: -0.18 (NI 96.4m - CFO 272.7m) / TA 957.3m) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 183.91 with a total of 86,047 shares traded. Over the past week, the price has changed by -6.42%, over one month by +37.65%, over three months by +82.00% and over the past year by +56.37%.
Current recommended Stop Loss: 155.50 (which is 15.4% or 2.7 ATR below the current price).
Nutex Health has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy NUTX.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 246.4 | 34% |
P/E Trailing = 14.3662
P/S = 1.5369
P/B = 3.7897
Revenue TTM = 880.0m USD
EBIT TTM = 276.2m USD
EBITDA TTM = 297.2m USD
Long Term Debt = 24.3m USD (from longTermDebt, last quarter)
Short Term Debt = 26.4m USD (from shortTermDebt, last quarter)
Debt = 657.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 308.0m
Net Debt = 449.7m USD (calculated: Debt 657.0m - CCE 207.3m)
Enterprise Value = 1.80b USD (1.35b + Debt 657.0m - CCE 207.3m)
Interest Coverage Ratio = 13.29 (Ebit TTM 276.2m / Interest Expense TTM 20.8m)
EV/FCF = 6.70x (Enterprise Value 1.80b / FCF TTM 269.0m)
FCF Yield = 14.93% (FCF TTM 269.0m / Enterprise Value 1.80b)
FCF Margin = 30.57% (FCF TTM 269.0m / Revenue TTM 880.0m)
Net Margin = 10.95% (Net Income TTM 96.4m / Revenue TTM 880.0m)
Gross Margin = 47.47% ((Revenue TTM 880.0m - Cost of Revenue TTM 462.3m) / Revenue TTM)
Gross Margin QoQ = 42.37% (prev 30.42%)
Tobins Q-Ratio = 1.88 (Enterprise Value 1.80b / Total Assets 957.3m)
Interest Expense / Debt = 3.16% (Interest Expense 20.8m / Debt 657.0m)
Taxrate = 23.11% (57.8m / 250.1m)
NOPAT = 212.4m (EBIT 276.2m * (1 - 23.11%))
Current Ratio = 3.14 (Total Current Assets 579.6m / Total Current Liabilities 184.4m)
Debt / Equity = 1.90 (Debt 657.0m / totalStockholderEquity, last quarter 346.3m)
Debt / EBITDA = 1.51 (Net Debt 449.7m / EBITDA 297.2m)
Debt / FCF = 1.67 (Net Debt 449.7m / FCF TTM 269.0m)
Total Stockholder Equity = 307.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.21% (Net Income 96.4m / Total Assets 957.3m)
RoE = 31.39% (Net Income TTM 96.4m / Total Stockholder Equity 307.0m)
RoCE = 83.38% (EBIT 276.2m / Capital Employed (Equity 307.0m + L.T.Debt 24.3m))
RoIC = 28.12% (NOPAT 212.4m / Invested Capital 755.3m)
WACC = 9.51% (E(1.35b)/V(2.01b) * Re(12.95%) + D(657.0m)/V(2.01b) * Rd(3.16%) * (1-Tc(0.23)))
Discount Rate = 12.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.19 | Cagr: 28.24%
[DCF] Terminal Value 74.30% ; FCFF base≈189.2m ; Y1≈216.9m ; Y5≈319.2m
[DCF] Fair Price = 514.1 (EV 3.99b - Net Debt 449.7m = Equity 3.54b / Shares 6.88m; r=9.51% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 95.95 | Revenue CAGR: 91.84% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=4.95 | Chg30d=+6.69% | Revisions=+40% | Analysts=5
EPS next Quarter (2026-09-30): EPS=5.02 | Chg30d=+1.20% | Revisions=+40% | Analysts=5
EPS current Year (2026-12-31): EPS=21.52 | Chg30d=+2.38% | Revisions=+40% | GrowthEPS=+105.3% | GrowthRev=+0.6%
EPS next Year (2027-12-31): EPS=23.03 | Chg30d=+2.60% | Revisions=+40% | GrowthEPS=+7.0% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: +73% (up=8, down=0)